Aptevo Therapeutics Inc.
1.4200-0.04 (-2.74%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · APVO · USD
Key Stats
Market Cap
19.61MP/E (TTM)
0.00Basic EPS (TTM)
2680.54Dividend Yield
0%Recent Filings
8-K
100% remission in AML trial cohort
Aptevo Therapeutics announced a 100% remission rate in Cohort 3 of its Phase 1b/2 RAINIER trial, testing mipletamig with venetoclax and azacitidine in newly diagnosed AML patients unfit for intensive chemotherapy. No dose-limiting toxicities or cytokine release syndrome emerged across cohorts, highlighting mipletamig's clean safety profile. This bolsters mipletamig's frontline potential in a multibillion-dollar AML market. Cohort 4 enrollment is underway.
8-K
Aptevo files trispecific patents
Aptevo Therapeutics expanded its oncology pipeline on September 4, 2025, by filing provisional patents for two trispecific candidates, APVO452 and APVO451, targeting prostate cancer and other solid tumors via PSMA or Nectin-4, CD3, and CD40. These molecules, built on the ADAPTIR-FLEX platform, aim to activate T cells while reprogramming the immunosuppressive tumor microenvironment, building on mipletamig's clinical validation in AML. Preclinical data show tumor-specific immune activation without systemic toxicity. Provisional patents may not fully protect these innovations.
8-K
Aptevo expands pipeline, raises funds
Aptevo Therapeutics expanded its CD3 bispecific pipeline by introducing APVO455, a Nectin-4 x CD3 engager targeting solid tumors like bladder and breast cancers, building on mipletamig's 85% remission rate in frontline AML patients across two trials. The company raised $15.9 million in Q2 2025, boosting cash to $9.4 million and extending runway into late Q4. Mipletamig shines without CRS events. Yet clinical risks loom large.
10-Q
Q2 FY2025 results
Aptevo Therapeutics narrowed its Q2 operating loss to $6.2 million from $6.0 million a year earlier, while YTD net loss widened slightly to $12.6 million from $12.7 million, driven by higher mipletamig trial enrollment costs that offset cuts in ALG.APV-527 escalation. Research expenses dipped 8.6% y/y to $3.3 million in the quarter, reflecting a ramp-down in preclinical work, but gross margins remain undefined without revenue. Cash climbed to $9.4 million on $15.9 million from equity raises, including a $25 million SEPA line, funding runway into late 2025 despite $13.7 million YTD operating burn. No debt burdens or M&A events noted. Yet competition in bispecific oncology intensifies, pressuring pipeline timelines.
8-K
Aptevo annual meeting approvals
Aptevo Therapeutics held its 2025 Annual Meeting on July 24, electing Marvin L. White and John E. Niederhuber, M.D., to the board until 2028. Shareholders ratified Baker Tilly US, LLP as auditors for the year ending December 31, 2025, and approved a reverse stock split at a 1-for-6 to 1-for-20 ratio, plus stock issuances under the Yorkville SEPA and warrant exercises. All proposals passed, bolstering governance and financing flexibility amid Nasdaq compliance. Yet, broker non-votes highlight investor caution.
IPO
Employees
Sector
Industry
ADAP
Adaptimmune Therapeutics plc
0.05+0.00
ADPT
Adaptive Biotechnologies Corpor
16.80-0.10
ALLO
Allogene Therapeutics, Inc.
1.22-0.04
ALXO
ALX Oncology Holdings Inc.
1.59+0.05
APLM
Apollomics Inc.
14.11-6.75
APLT
Applied Therapeutics, Inc.
1.22-0.08
APTOF
Aptose Biosciences. Inc.
1.25-0.01
IMTX
Immatics N.V.
10.34-0.02
MRKR
Marker Therapeutics, Inc.
0.97-0.04
RAPT
RAPT Therapeutics, Inc.
29.78-0.35